JP2022041802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022041802A5 JP2022041802A5 JP2020187708A JP2020187708A JP2022041802A5 JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5 JP 2020187708 A JP2020187708 A JP 2020187708A JP 2020187708 A JP2020187708 A JP 2020187708A JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- weeks
- administered
- pharmaceutical composition
- pruritus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 40
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 208000003251 Pruritus Diseases 0.000 claims 24
- 238000000502 dialysis Methods 0.000 claims 24
- 238000011282 treatment Methods 0.000 claims 14
- 238000011321 prophylaxis Methods 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 208000019116 sleep disease Diseases 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 230000004044 response Effects 0.000 claims 3
- 208000022925 sleep disturbance Diseases 0.000 claims 3
- 238000009121 systemic therapy Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 claims 2
- 101710131691 Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 239000004909 Moisturizer Substances 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 239000000043 antiallergic agent Substances 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 230000009260 cross reactivity Effects 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001333 moisturizer Effects 0.000 claims 2
- 229960000441 nalfurafine Drugs 0.000 claims 2
- XGZZHZMWIXFATA-UEZBDDGYSA-N nalfurafine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3N(C)C(=O)\C=C\C1=COC=C1)CN2CC1CC1 XGZZHZMWIXFATA-UEZBDDGYSA-N 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000004620 sleep latency Effects 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020187708A JP7548784B2 (ja) | 2020-09-01 | 2020-11-11 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020551453A JP6799831B1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
| PCT/JP2020/032987 WO2022049614A1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
| JP2020187708A JP7548784B2 (ja) | 2020-09-01 | 2020-11-11 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551453A Division JP6799831B1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022041802A JP2022041802A (ja) | 2022-03-11 |
| JP2022041802A5 true JP2022041802A5 (OSRAM) | 2023-07-26 |
| JP7548784B2 JP7548784B2 (ja) | 2024-09-10 |
Family
ID=73741045
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551453A Active JP6799831B1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
| JP2020187708A Active JP7548784B2 (ja) | 2020-09-01 | 2020-11-11 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551453A Active JP6799831B1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230391878A1 (OSRAM) |
| EP (1) | EP4209227A4 (OSRAM) |
| JP (2) | JP6799831B1 (OSRAM) |
| KR (2) | KR102800698B1 (OSRAM) |
| CN (1) | CN116096411A (OSRAM) |
| AU (1) | AU2020466800A1 (OSRAM) |
| CA (1) | CA3189847A1 (OSRAM) |
| IL (1) | IL300694A (OSRAM) |
| MX (1) | MX2023002482A (OSRAM) |
| WO (1) | WO2022049614A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016167263A1 (ja) | 2015-04-14 | 2016-10-20 | 中外製薬株式会社 | Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| ES3036076T3 (en) | 2015-04-14 | 2025-09-12 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| BR112022006590A2 (pt) | 2019-11-20 | 2022-06-28 | Chugai Pharmaceutical Co Ltd | Preparação contendo anticorpos |
| WO2025167991A1 (zh) * | 2024-02-07 | 2025-08-14 | 武汉人福创新药物研发中心有限公司 | 一种靶向il-31ra的抗体或其抗原结合片段及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| JP2002338476A (ja) * | 2001-05-21 | 2002-11-27 | Health Factor Kenkyusho:Kk | 腎透析に伴う痒みの予防治療剤 |
| JP4511349B2 (ja) | 2002-01-18 | 2010-07-28 | ザイモジェネティクス，インコーポレイティド | サイトカイン受容体ｚｃｙｔｏｒ１７マルチマー |
| EP1713325A2 (en) | 2004-02-12 | 2006-10-25 | Lexicon Genetics Incorporated | Gene disruptions, compositions and methods relating thereto |
| EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| EP1856150A2 (en) | 2005-02-14 | 2007-11-21 | ZymoGenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| WO2006088855A1 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| CN101589060A (zh) * | 2006-01-10 | 2009-11-25 | 津莫吉尼蒂克斯公司 | 使用il-31拮抗剂在神经元性组织中治疗疼痛和炎症的方法 |
| MX2008008831A (es) * | 2006-01-10 | 2009-03-04 | Zymogenetics Inc | Metodos para tratar dolor e inflamacion en tejidos neuronales usando antagonistas il-31. |
| PE20080333A1 (es) | 2006-06-08 | 2008-06-15 | Chugai Pharmaceutical Co Ltd | Agentes para prevenir o tratar enfermedades inflamatorias |
| DK2594586T3 (en) | 2006-09-01 | 2014-11-17 | Zymogenetics Inc | Monoclonal il-31 antibodies and methods of use thereof |
| MX337081B (es) | 2007-12-05 | 2016-02-10 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-nr10 y su uso. |
| MY162546A (en) | 2007-12-05 | 2017-06-15 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
| AU2008333131B2 (en) | 2007-12-07 | 2013-10-24 | Merck Serono S/A | Humanized antibody molecules specific for IL-31 |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| JP5650871B1 (ja) * | 2013-06-28 | 2015-01-07 | 中外製薬株式会社 | そう痒を伴う疾患に罹患した患者のｉｌ−３１アンタゴニストによる治療に対する応答を予測する方法 |
| WO2015025767A1 (ja) * | 2013-08-21 | 2015-02-26 | 久光製薬株式会社 | 貼付剤 |
| US20190135804A1 (en) * | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| KR102156932B1 (ko) * | 2017-11-23 | 2020-09-17 | 주식회사 헬릭스미스 | 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물 |
| WO2019229525A2 (en) * | 2018-04-25 | 2019-12-05 | Kiniksa Pharmaceuticals, Ltd. | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY |
-
2020
- 2020-09-01 JP JP2020551453A patent/JP6799831B1/ja active Active
- 2020-09-01 WO PCT/JP2020/032987 patent/WO2022049614A1/ja not_active Ceased
- 2020-09-01 AU AU2020466800A patent/AU2020466800A1/en active Pending
- 2020-09-01 KR KR1020217018823A patent/KR102800698B1/ko active Active
- 2020-09-01 US US18/023,246 patent/US20230391878A1/en active Pending
- 2020-09-01 IL IL300694A patent/IL300694A/en unknown
- 2020-09-01 EP EP20952354.7A patent/EP4209227A4/en active Pending
- 2020-09-01 CA CA3189847A patent/CA3189847A1/en active Pending
- 2020-09-01 MX MX2023002482A patent/MX2023002482A/es unknown
- 2020-09-01 KR KR1020207030800A patent/KR102269716B1/ko active Active
- 2020-09-01 CN CN202080103639.6A patent/CN116096411A/zh active Pending
- 2020-11-11 JP JP2020187708A patent/JP7548784B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022041802A5 (OSRAM) | ||
| Kuriyama et al. | Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis | |
| TWI738648B (zh) | 含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物 | |
| JP2017160178A5 (OSRAM) | ||
| JP2010509369A5 (OSRAM) | ||
| Khan et al. | Tramadol use in premature ejaculation: daily versus sporadic treatment | |
| US11123329B1 (en) | Use of angiotensin II type 2 receptor agonist | |
| Goodman et al. | Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy) | |
| CN111372948A (zh) | 用il-17拮抗剂治疗化脓性汗腺炎 | |
| JP7309816B2 (ja) | 結節性痒疹患者における皮膚病変およびそう痒の治療 | |
| JP2018515493A5 (OSRAM) | ||
| KR20220112803A (ko) | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 | |
| JP2018534259A5 (OSRAM) | ||
| Aggarwal et al. | Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study | |
| Saco et al. | Prurigo nodularis: Picking the right treatment. | |
| EP2844291A1 (en) | Methods for treating idiopathic pulmonary fibrosis | |
| JP2015522077A5 (OSRAM) | ||
| KR20180017145A (ko) | 소양증의 치료 | |
| JP2025176134A (ja) | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ | |
| KR20230054444A (ko) | 호흡기 질환 치료에 사용하기 위한 (1r,3s)-3-((5-시아노-4-페닐티아졸-2-일)카바모일)사이클로펜탄-1-카르복시산 및 이의 유도체 | |
| Svecova et al. | Clinical manifestation variability of bullous pemphigoid. | |
| Lewis et al. | Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate | |
| AU2015305430A1 (en) | Method for treating hyperhidrosis | |
| JPWO2020039256A5 (OSRAM) | ||
| Skoner | Montelukast in 2‐to 5‐year‐old children with asthma |